Additionally, SGLT‐2 inhibitors are associated with increased levels of haemoglobin and haematocrit which could provide benefits to SCD patients, especially since the increased haemoglobin is linked to other protective effects of SGLT‐2 inhibition.5 This evidence concerns the gene SLC5A2 and Schnyder corneal dystrophy.